Bank of Montreal
TSHA icon

Bank of Montreal’s Taysha Gene Therapies TSHA Stock Holding History

Bank of Montreal’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.1K Sell
13,668
-40
-0.3% -$186 ﹤0.01% 3245
2025
Q4 		$75.4K Buy
13,708
+40
+0.3% +$194 ﹤0.01% 3111
2025
Q3 		$44.7K Buy
+13,668
New +$38.7K ﹤0.01% 3147
2023
Q2 		– Sell
-49,084
Closed -$40.2K – 4293
2023
Q1 		$40.2K Sell
49,084
-153,115
-76% -$198K ﹤0.01% 3410
2022
Q4 		$459K Buy
+202,199
New +$409K ﹤0.01% 2660
2021
Q2 		– Sell
-268
Closed -$5K – 4872
2021
Q1 		$5K Sell
268
-1,096
-80% -$29.7K ﹤0.01% 4669
2020
Q4 		$38K Buy
+1,364
New +$29.4K ﹤0.01% 4090

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bank of Montreal's TSHA Position: Q1 2026 in Review

Bank of Montreal reduced its Taysha Gene Therapies (TSHA) stake by 0.29% in Q1 2026, selling an estimated $186 and leaving 13,668 shares worth $61.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3245.

Bank of Montreal first reported a position in TSHA in Q4 2020 and has held it in 7 quarters since. The position peaked at $459K in Q4 2022. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Bank of Montreal held 13,668 shares of Taysha Gene Therapies worth $61.1K as of Q1 2026.
  • Bank of Montreal sold 40 Taysha Gene Therapies shares in Q1 2026, an estimated $186.
  • Taysha Gene Therapies made up ﹤0.01% of Bank of Montreal's portfolio in Q1 2026, its #3245 holding.
  • Bank of Montreal first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 7 quarters since.
  • Bank of Montreal's Taysha Gene Therapies position peaked at $459K in Q4 2022.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.